ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      AI Subscribe Login/Register Profile Icon
      S&P 500
      5,702.55
      -0.19%
      US Tech 100
      19,287.60
      -0.24%
      Dow Jones
      42,063.36
      0.09%
      Brent Oil
      74.405
      0.70%
      Bitcoin
      63,757.66
      0.21%
      Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ

      6. Akebia Therapeutics Inc (AKBA) Quote

      Akebia Therapeutics Inc

      Akebia Therapeutics Inc (AKBA)

      NASDAQ
      1.36
      -0.01
      (-0.73%)
      Closed September 23 4:00PM
      Delayed by 15 minutes
      1.38
      0.02
      (1.47%)
      After Hours: 7:42PM
      Delayed by 15 minutes

      Professional-Grade Tools, for Individual Investors.

      Premium

      Key stats and details

      Current Price
      1.38
      Bid
      1.32
      Ask
      1.48
      Volume
      3,558,730
      1.335 Day's Range 1.40
      0.7801 52 Week Range 2.48
      Market Cap
      290.198M
      Previous Close
      1.37
      Open
      1.36
      Last Trade
      720
      @
      1.38
      (formt)
      Last Trade Time
      Financial Volume
      $ 4,830,877
      VWAP
      1.3575
      Average Volume (3m)
      2,071,140
      Shares Outstanding
      210,288,210
      Dividend Yield
      -
      PE Ratio
      -5.51
      Earnings Per Share (EPS)
      -0.25
      Revenue
      194.62M
      Net Profit
      -51.93M

      About Akebia Therapeutics Inc

      Akebia Therapeutics Inc is a biopharmaceutical company. It focuses on the development and commercialization of novel therapeutics to patients with kidney disease through hypoxia-inducible factor (HIF) biology. Its lead product candidate is Vadadustat, an oral therapy, which is used for the treatment... Akebia Therapeutics Inc is a biopharmaceutical company. It focuses on the development and commercialization of novel therapeutics to patients with kidney disease through hypoxia-inducible factor (HIF) biology. Its lead product candidate is Vadadustat, an oral therapy, which is used for the treatment of anemia related to chronic kidney disease in non-dialysis and dialysis patients. The company is also developing a HIF-based portfolio of product for the treatment of anemia. Geographically, all the business activity is functioned through the region of United States. Show more

      Sector
      Pharmaceutical Preparations
      Industry
      Pharmaceutical Preparations
      Website
      www.akebia.com
      Headquarters
      Wilmington, Delaware, USA
      Founded
      -
      Akebia Therapeutics Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker AKBA. The last closing price for Akebia Therapeutics was $1.37. Over the last year, Akebia Therapeutics shares have traded in a share price range of $ 0.7801 to $ 2.48.

      Akebia Therapeutics currently has 210,288,210 shares outstanding. The market capitalization of Akebia Therapeutics is $288.09 million. Akebia Therapeutics has a price to earnings ratio (PE ratio) of -5.51.

      Ask ADVFN Intelligence (AI)

      AKBA Latest News

      More News

      Form EFFECT - Notice of Effectiveness

      September 13 2024
      Edgar (US Regulatory)

      Akebia Therapeutics and U.S. Renal Care Initiate the VOICE Trial of Vafseo® (vadadustat) for Patients on Dialysis

      Akebia Therapeutics and U.S. Renal Care Initiate the VOICE Trial of Vafseo® (vadadustat) for Patients on Dialysis PR Newswire CAMBRIDGE, Mass., Sept. 5, 2024 Outcomes study will assess mortality...

      September 05 2024
      PR Newswire (US)

      Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire CAMBRIDGE, Mass., Sept. 3, 2024 CAMBRIDGE, Mass., Sept. 3, 2024 /PRNewswire/ -- Akebia...

      September 03 2024
      PR Newswire (US)

      Form S-3 - Registration statement under Securities Act of 1933

      September 03 2024
      Edgar (US Regulatory)

      Akebia Therapeutics to Present at Upcoming Investor Conferences

      Akebia Therapeutics to Present at Upcoming Investor Conferences PR Newswire CAMBRIDGE, Mass., Aug. 26, 2024 CAMBRIDGE, Mass., Aug. 26, 2024 /PRNewswire/ -- Akebia Therapeutics®, Inc. (Nasdaq:...

      August 26 2024
      PR Newswire (US)

      Form 10-Q - Quarterly report [Sections 13 or 15(d)]

      August 08 2024
      Edgar (US Regulatory)

      Form 8-K - Current report

      August 08 2024
      Edgar (US Regulatory)

      Akebia Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights

      Akebia Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights PR Newswire CAMBRIDGE, Mass., Aug. 8, 2024 Vafseo® (vadadustat) Tablets market availability on...

      August 08 2024
      PR Newswire (US)

      Akebia Therapeutics to Report Second Quarter 2024 Financial Results and Discuss Recent Business Highlights

      Akebia Therapeutics to Report Second Quarter 2024 Financial Results and Discuss Recent Business Highlights PR Newswire CAMBRIDGE, Mass., Aug. 2, 2024 Akebia to Host Conference Call on August 8...

      August 02 2024
      PR Newswire (US)

      Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire CAMBRIDGE, Mass., Aug. 1, 2024 CAMBRIDGE, Mass., Aug. 1, 2024 /PRNewswire/ -- Akebia Therapeutics®...

      August 01 2024
      PR Newswire (US)
      PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
      1-0.07-4.82758620691.451.4851.3411795331.39053248CS
      4-0.14-9.210526315791.521.581.2715470641.44948467CS
      120.3533.98058252431.031.580.9120711401.31379586CS
      26-0.49-26.20320855611.872.480.834738761.45842782CS
      520.1512.19512195121.232.480.780127065631.42229453CS
      156-1.41-50.53763440862.793.350.24136475311.08137405CS
      260-3.13-69.40133037694.5113.780.24136103312.308726CS

      Movers

      View all
      • Most Active
      • % Gainers
      • % Losers
      SymbolPriceVol.
      BNZIBanzai International Inc
      $ 5.645
      (96.01%)
      		61.39M
      ZJYLJin Medical International Ltd
      $ 3.975
      (50.00%)
      		1.24M
      ANEBAnebulo Pharmaceuticals Inc
      $ 2.9001
      (39.43%)
      		78.85k
      XPONExpion360 Inc
      $ 0.081
      (39.18%)
      		1.46B
      AENTAlliance Entertainment Holding Corporation
      $ 2.74
      (34.31%)
      		4.23M
      GSIWGarden Stage Ltd
      $ 1.34
      (-82.89%)
      		26.44M
      CRBPCorbus Pharmaceuticals Holdings Inc
      $ 19.51
      (-62.26%)
      		12.29M
      LGCBLinkage Global Inc
      $ 0.4183
      (-57.70%)
      		2.16M
      BFIBurgerFi International Inc
      $ 0.0855
      (-42.27%)
      		15.05M
      SKYESkye Bioscience Inc
      $ 3.17
      (-42.26%)
      		5.14M
      XPONExpion360 Inc
      $ 0.081
      (39.18%)
      		1.46B
      NVDANVIDIA Corporation
      $ 116.00
      (-1.59%)
      		378.16M
      AAPLApple Inc
      $ 228.20
      (-0.29%)
      		320.24M
      INTCIntel Corporation
      $ 21.84
      (3.31%)
      		261.68M
      VERBVerb Technology Company Inc
      $ 0.0742
      (33.45%)
      		178.65M

      AKBA Discussion

      View Posts
      glenn1919 glenn1919 4 weeks ago
      AKBA.....................................https://stockcharts.com/h-sc/ui?s=AKBA&p=W&b=5&g=0&id=p86431144783
      👍️0
      glenn1919 glenn1919 1 month ago
      AKBA................................https://stockcharts.com/h-sc/ui?s=ARKB&p=W&b=5&g=0&id=p86431144783
      👍️0
      glenn1919 glenn1919 1 month ago
      AKBA......................................https://stockcharts.com/h-sc/ui?s=AKBA&p=W&b=5&g=0&id=p86431144783
      👍️0
      glenn1919 glenn1919 2 months ago
      AKBA...........................https://stockcharts.com/h-sc/ui?s=AKBA&p=W&b=5&g=0&id=p86431144783
      👍️0
      Krspecialized Krspecialized 2 months ago
      I believe the current news releases may have answered your question. GLTA
      👍️0
      Toofuzzy Toofuzzy 4 months ago
      Why do you say we have a gold mine here ?

      Toofuzzy
      👍️0
      Krspecialized Krspecialized 4 months ago
      There's no doubt we have a gold mine here, and at some point it will be load up time. Figuring out when is the big question!
      👍️0
      eyeownu eyeownu 4 months ago
      SCARY MOVIE
      👍️0
      eyeownu eyeownu 4 months ago
      https://journey.ct.events/view/a825b116-e5ee-4e76-ad8d-2e9e9116aa21 tomorrows web cast
      👍️0
      eyeownu eyeownu 4 months ago
      added 2k@ 1.11
      👍️ 1
      glenn1919 glenn1919 5 months ago
      AKBA................................https://stockcharts.com/h-sc/ui?s=AKBA&p=W&b=5&g=0&id=p86431144783
      👍️0
      Monksdream Monksdream 5 months ago
      AKBA under $2

      👍️0
      eyeownu eyeownu 5 months ago
      ask is stacked! someone needs to slap it.
      👍️0
      eyeownu eyeownu 5 months ago
      $AKBA RELOAD
      👍️0
      Firestorm22 Firestorm22 5 months ago
      Starting to remind me of a “pump and dump” stock. Spikes up but always comes back down to where it started.
      👍️0
      Firestorm22 Firestorm22 5 months ago
      Starting to remind me of a “pump and dump” stock. Spikes up but always comes back down to where it started.
      👍️0
      ErnieBilco ErnieBilco 6 months ago
      I'm in at 33 cents so I'm not going anywhere, just gonna let it ride wherever it goes
      👍️ 1
      Firestorm22 Firestorm22 6 months ago
      Thanks, I’m hanging onto it . With actual revenues of 40-60 mill the last 5 quarters, one would think this stock price should rise. I wouldn’t mind seeing them bought out.
      👍️ 1
      ErnieBilco ErnieBilco 6 months ago
      Classic sell the news. Probable offering coming next week to dilute on the good news.
      👍️0
      Firestorm22 Firestorm22 6 months ago
      Something just isnt right here. How do you get FDA approval for a drug and your stock price tank? Is there some bads news getting ready to come out on this company??
      👍️0
      Krspecialized Krspecialized 6 months ago
      Long solid position here!
      👍️0
      Limey42 Limey42 6 months ago
      Long term play. Congrats all!
      👍️ 1
      dugie100 dugie100 6 months ago
      Something didn’t look good , I guess!
      👍️0
      TrendTrade2016 TrendTrade2016 6 months ago
      AKBA should see 3 bucks
      👍️0
      TrendTrade2016 TrendTrade2016 6 months ago
      AKBA...FDA EXPLOSION ...WE LOADED THIS BEAUTY....KOCKED AND LOADED!!!!
      👍️0
      glenn1919 glenn1919 6 months ago
      AKBA...................................https://stockcharts.com/h-sc/ui?s=AKBA&p=W&b=5&g=0&id=p86431144783
      👍️0
      Monksdream Monksdream 6 months ago
      AKBA new 52 hi
      👍️0
      eyeownu eyeownu 6 months ago
      $AKBA looking good damn! she fine.
      👍️ 1
      glenn1919 glenn1919 6 months ago
      AKBA.................................https://stockcharts.com/h-sc/ui?s=AKBA&p=W&b=5&g=0&id=p86431144783
      👍️0
      eyeownu eyeownu 6 months ago
      $AKBA from stocktwits FDA’S THREE ALARM FIRE- (a)FDA issued CRL to FibroGen & Roxadustat (Aug. 2021); (b)FDA issued CRL to Akebia & Vadadustat (March 2022); (c)FDA’s Cardiovascular & Renal Drugs Advisory Committee supported GSK’s Daprodustat for dialysis dependent patients w/ anaemia of CKD w/ 13-3 vote (Oct. 2022); (d)Akebia submitted FDRR w/ FDA’s Senior Advisor in agency’s Office of New Drugs (OND) (Nov. 2022); (e)CKD community & key opinion leaders such as Dr. Jay Wish criticize FDA decision making concerning HIF-PHI drugs (March 2022 - present). (FDA knows from data that Daprodustat is inferior to Vadadustat.) FDA’S RESPONSE TO FIRE - (a)FDA met w/ Akebia to discuss appeal & subsequently requested “additional clarifying information” (not ADCOM, not clinical trial, not denial) (Nov. 2022); (b)FDA assigned Dr. Peter Stein, M.D., Director of OND as deciding authority for appeal (Feb. 2023); (c)Dr. Stein provided Akebia/Vadadustat w/ clear path forward to approval (May 2023). GLTA
      👍️ 1
      Monksdream Monksdream 7 months ago
      AKBA 10Q March 4
      👍️0
      Tyrus603 Tyrus603 7 months ago
      Excellent chart. Thank you for posting.

      Found myself studying it for quite a bit.

      As it really is a dream chart for both swing traders AND long term buy & hold investors alike.
      👍️0
      glenn1919 glenn1919 7 months ago
      AKBA..............................................https://stockcharts.com/h-sc/ui?s=AKBA&p=W&b=5&g=0&id=p86431144783
      👍️0
      eyeownu eyeownu 7 months ago
      $AKBA
      👍️0
      eyeownu eyeownu 7 months ago
      $AKBA reversal incoming?
      👍️0
      eyeownu eyeownu 8 months ago
      CAMBRIDGE, Mass., Jan. 30, 2024 /PRNewswire/ -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced it has closed a loan facility with funds and accounts managed by BlackRock. The loan provides Akebia with up to $55.0 million of borrowing capacity available in three tranches.

      At the closing, Akebia drew the first tranche of $37.0 million and used the proceeds to pay down $35.0 million of principal outstanding from a loan agreement with Pharmakon Advisors, LP (Pharmakon), the investment manager of the BioPharma Credit funds, plus interest and fees. The new agreement substantially extends the interest-only period in the event of vadadustat approval by the U.S. Food and Drug Administration (FDA) without requiring any principal repayment until December 31, 2025, with an option for Akebia to extend until December 31, 2026.
      👍️0
      eyeownu eyeownu 8 months ago
      $AKBA profit taking! hope you took some off the table!
      👍️0
      eyeownu eyeownu 8 months ago
      PDUFA explanation https://www.fool.com/terms/p/pdufa-date/

      What percentage of PDUFA are approved?
      Characteristic Percentage of drugs approved in 2023
      Met PDUFA goal date* 89%
      First cycle of review 84%
      Approved in the United States before receiving approval in any other country 64%
      Priority review 56%

      From
      👍️0
      eyeownu eyeownu 8 months ago
      $AKBA via stocktwit @Bidzill @fresh10 fresh - We have PDUFA date scheduled for March 27, 2024 concerning Vadadustat DD USA. Approval is de-risked and highly likely, IMO. We have product launch date first half of year for Vadadustat DD EU/Australia. We have phase 2 trial for AKB 9090 for second half of 2024. We have Auryxia all time/near all time high sales 2024. Good luck 🍀 to you and us.
      👍️0
      eyeownu eyeownu 8 months ago
      https://www.tradingview.com/x/6Ykwijbc/
      👍️0
      eyeownu eyeownu 8 months ago
      $AKBA from stocktwits

      MORE GOOD NEWS - FDA Fast Track Designation is process designed to facilitate development & expedite drug review to treat serious conditions & fill UNMET MEDICAL NEED. Determining whether condition is serious enough for designation is matter of judgment … ARDS is life threatening & acute, diffuse, inflammatory form of lung injury in seriously ill patients characterized by poor oxygenation, pulmonary infiltrates, acute onset. Unadjusted hospitalization mortality was reported to be 35% among those w/ mild ARDS, 40% w/ moderate disease, 46% for patients w/ severe ARDS. AKB 9090 is Akebia’s ARDS drug. Filling an unmet need is defined as providing therapy where none exists or which may be potentially better than available therapy. Drug that receives Fast Track is eligible for accelerated approval/priority review. August of 2022, CEO Butler said Vadadustat was in trials for Covid-19/ARDS which was an “unmet medical need.” Butler was signaling intention to go after Fast Track status.
      https://stocktwits.com/buythehornz127/message/559186953
      👍️0
      eyeownu eyeownu 8 months ago
      John P. Butler, President and Chief Executive Officer of Akebia Therapeutics, Inc. (the “Company”), plans to present the information in the presentation attached hereto as Exhibit 99.1 (the “Presentation”) at the 42 Annual J.P. Morgan
      Healthcare Conference on January 11, 2024 at 11:15 a.m. PST, which includes preliminary unaudited net product revenue for Auryxia® cumulative and for the fiscal year ended December 31, 2023. Spokespersons of the Company also plan
      to present the information in the Presentation at various meetings beginning on January 8, 2024, including investor and analyst meetings that coincide with the J.P. Morgan Healthcare Conference

      https://ir.akebia.com/static-files/0be66d7f-9988-43fa-bcab-e587260e1dc0
      👍️0
      eyeownu eyeownu 8 months ago
      easy money https://schrts.co/JdqbEsCN wait till the real news drops!
      👍️0
      eyeownu eyeownu 8 months ago
      $AKBA shabba https://schrts.co/bYSHjBzF
      👍️0
      eyeownu eyeownu 8 months ago
      this is looking good. if the RSI ever resets i'm going all in!
      👍️0
      eyeownu eyeownu 9 months ago
      end of year. double top forming or is it slow and steady?
      👍️0
      glenn1919 glenn1919 1 year ago
      AKBA...........................https://stockcharts.com/h-sc/ui?s=AKBA&p=W&b=5&g=0&id=p86431144783
      👍️0
      TrendTrade2016 TrendTrade2016 1 year ago
      AKBA full out weekly trend in place
      👍️0
      TrendTrade2016 TrendTrade2016 1 year ago
      AKBA MONSTER BREAK OUT
      👍️0
      glenn1919 glenn1919 1 year ago
      AKBA...........................https://stockcharts.com/h-sc/ui?s=AKBA&p=W&b=5&g=0&id=p86431144783
      👍️0

      Your Recent History

      NASDAQ
      AKBA
      Akebia Therapeutics
      Delayed Upgrade Clock